Evidence map›Paper›PMID 27429798›Full record

ReviewJournal of ophthalmology2016

Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years.

Salvatore Di Lauro, Mustafa R Kadhim, David G Charteris, J Carlos Pastor

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06541574 (Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair), which is not on this map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06541574 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

TypeinterventionalSponsorCincinnati Eye Institute, Southwest OhioRan2024 to 2026Enrolled860ConditionsProliferative Vitreoretinopathy, Rhegmatogenous Retinal DetachmentArmsMethotrexate Injection, Methotrexate Infusion, Sham Injection
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Methotrexate as an adjunct to pars plana vitrectomy for the prevention and treatment of proliferative vitreoretinopathy in rhegmatogenous retinal detachment: A clinical study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Fibrotic Changes in Rhegmatogenous Retinal Detachment.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Proliferative Vitreoretinopathy: A Reappraisal.Journal of clinical medicine · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Salvatore Di LauroIOBA (Eye Institute), University of Valladolid, 47011 Valladolid, Spain; Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.ORCID 0000-0002-2079-0252
Mustafa R KadhimMoorfields Eye Hospital, London EC1V 2PD, UK.
David G CharterisMoorfields Eye Hospital, London EC1V 2PD, UK.
J Carlos PastorIOBA (Eye Institute), University of Valladolid, 47011 Valladolid, Spain; Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.ORCID 0000-0001-5934-7306

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose. To evaluate the current and suitable use of current proliferative vitreoretinopathy (PVR) classifications in clinical publications related to treatment. Methods. A PubMed search was undertaken using the term "proliferative vitreoretinopathy therapy". Outcome parameters were the reported PVR classification and PVR grades. The way the classifications were used in comparison to the original description was analyzed. Classification errors were also included. It was also noted whether classifications were used for comparison before and after pharmacological or surgical treatment. Results. 138 papers were included. 35 of them (25.4%) presented no classification reference or did not use any one. 103 publications (74.6%) used a standardized classification. The updated Retina Society Classification, the first Retina Society Classification, and the Silicone Study Classification were cited in 56.3%, 33.9%, and 3.8% papers, respectively. Furthermore, 3 authors (2.9%) used modified-customized classifications and 4 (3.8%) classification errors were identified. When the updated Retina Society Classification was used, only 10.4% of authors used a full C grade description. Finally, only 2 authors reported PVR grade before and after treatment. Conclusions. Our findings suggest that current classifications are of limited value in clinical practice due to the inconsistent and limited use and that it may be of benefit to produce a revised classification.

Identifiers

PMID27429798
PMCPMC4939352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.